Small molecule · Modulator of Mutant p53 (TP53) (TP53) · developed by Aprea Therapeutics
Eprenetapopt is a methylated analogue of PRIMA-1 that covalently modifies mutated p53 through alkylation of thiol groups in its core domain. This is intended to restore wild-type conformation and function to the mutant protein, leading to cell cycle arrest and apoptosis in tumor cells. It is studied in myelodysplastic syndrome, acute myeloid leukemia, and several solid tumors and lymphomas.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03745716 | Phase 3 | MDS | Completed | APRE |
| NCT04419389 | Phase 1/2 | Non Hodgkin Lymphoma | Terminated | APRE |
| NCT04383938 | Phase 1/2 | Bladder Cancer | Completed | APRE |
| NCT03588078 | Phase 1/2 | Myelodysplastic Syndrome With Gene Mutation | Completed | APRE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute Myeloid Leukemia With Gene MutationsAdvanced Solid TumorBladder CancerChronic Lymphocytic LeukemiaChronic Myelomonocytic LeukemiaGastric CancerMantle Cell LymphomaMDSMyelodysplastic Syndrome With Gene MutationMyeloproliferative NeoplasmNon Hodgkin LymphomaNon Small Cell Lung CancerNSCLCUrothelial Carcinoma
Updated Oct 11, 2026. Something wrong or missing? Report it on the APRE page.
See APRE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
APRE catalysts and pipeline →